Experience with a new botulinum toxin type A (BTA) formulation in the treatment of sialorrhea

Purpose: We report our initial experience with a new BTA formulation free of complex proteins in the treatment of sialorrhea. Our aim was to collect data on the safety and efficacy profile of Xeomin injections in saliva glands in a mixed population in neurorehabilitation. Methods: Six patients with neurogenic dysphagia and clinical significant sialorrhea (idiopathic Parkinson's disease=2, multiple system atrophy=1 and stroke=3) underwent bilateral parotis injections with 50 units Xeomin in each gland (dilution: 2ml normal saline per 100 unit) using sonographic guidance. Patients were evaluated two to three month…